Report Detail

Request for Sample of this report

Pharma & Healthcare Global Radioimmunotherapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4669536
    • |
  • 22 January, 2026
    • |
  • Global
    • |
  • 129 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Radioimmunotherapy market size was valued at US$ 2775 million in 2025 and is forecast to a readjusted size of US$ 6998 million by 2032 with a CAGR of 14.3% during review period.
Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
Global key Companies of Radioimmunotherapy include Novartis, Bayer, etc. The top two players hold a share over 98%. North America is the largest market, with a share about 62%, followed by Europe and Asia-Pacific, with the share about 29% and 8%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 90%.
This report is a detailed and comprehensive analysis for global Radioimmunotherapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radioimmunotherapy market size and forecasts, in consumption value ($ Million), 2021-2032
Global Radioimmunotherapy market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Radioimmunotherapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Radioimmunotherapy market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Radioimmunotherapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Radioimmunotherapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Radioimmunotherapy market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Beta-emitting
Targeted Alpha Therapy
Market segment by Application
Solid Tumor
Non Hodgkin Lymphoma
Market segment by players, this report covers
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Radioimmunotherapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Radioimmunotherapy, with revenue, gross margin, and global market share of Radioimmunotherapy from 2021 to 2026.
Chapter 3, the Radioimmunotherapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Radioimmunotherapy market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Radioimmunotherapy.
Chapter 13, to describe Radioimmunotherapy research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Radioimmunotherapy by Type
    • 1.3.1 Overview: Global Radioimmunotherapy Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Radioimmunotherapy Consumption Value Market Share by Type in 2025
    • 1.3.3 Beta-emitting
    • 1.3.4 Targeted Alpha Therapy
  • 1.4 Global Radioimmunotherapy Market by Application
    • 1.4.1 Overview: Global Radioimmunotherapy Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Solid Tumor
    • 1.4.3 Non Hodgkin Lymphoma
  • 1.5 Global Radioimmunotherapy Market Size & Forecast
  • 1.6 Global Radioimmunotherapy Market Size and Forecast by Region
    • 1.6.1 Global Radioimmunotherapy Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Radioimmunotherapy Market Size by Region, (2021-2032)
    • 1.6.3 North America Radioimmunotherapy Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Radioimmunotherapy Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Radioimmunotherapy Market Size and Prospect (2021-2032)
    • 1.6.6 South America Radioimmunotherapy Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Radioimmunotherapy Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Bayer
    • 2.1.1 Bayer Details
    • 2.1.2 Bayer Major Business
    • 2.1.3 Bayer Radioimmunotherapy Product and Solutions
    • 2.1.4 Bayer Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Bayer Recent Developments and Future Plans
  • 2.2 Novartis
    • 2.2.1 Novartis Details
    • 2.2.2 Novartis Major Business
    • 2.2.3 Novartis Radioimmunotherapy Product and Solutions
    • 2.2.4 Novartis Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Novartis Recent Developments and Future Plans
  • 2.3 Lantheus
    • 2.3.1 Lantheus Details
    • 2.3.2 Lantheus Major Business
    • 2.3.3 Lantheus Radioimmunotherapy Product and Solutions
    • 2.3.4 Lantheus Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Lantheus Recent Developments and Future Plans
  • 2.4 Aurobindo Pharma
    • 2.4.1 Aurobindo Pharma Details
    • 2.4.2 Aurobindo Pharma Major Business
    • 2.4.3 Aurobindo Pharma Radioimmunotherapy Product and Solutions
    • 2.4.4 Aurobindo Pharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Aurobindo Pharma Recent Developments and Future Plans
  • 2.5 Mundipharma
    • 2.5.1 Mundipharma Details
    • 2.5.2 Mundipharma Major Business
    • 2.5.3 Mundipharma Radioimmunotherapy Product and Solutions
    • 2.5.4 Mundipharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Mundipharma Recent Developments and Future Plans
  • 2.6 China Isotope & Radiation
    • 2.6.1 China Isotope & Radiation Details
    • 2.6.2 China Isotope & Radiation Major Business
    • 2.6.3 China Isotope & Radiation Radioimmunotherapy Product and Solutions
    • 2.6.4 China Isotope & Radiation Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 China Isotope & Radiation Recent Developments and Future Plans
  • 2.7 Curium Pharmaceuticals
    • 2.7.1 Curium Pharmaceuticals Details
    • 2.7.2 Curium Pharmaceuticals Major Business
    • 2.7.3 Curium Pharmaceuticals Radioimmunotherapy Product and Solutions
    • 2.7.4 Curium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Curium Pharmaceuticals Recent Developments and Future Plans
  • 2.8 Gilead Sciences
    • 2.8.1 Gilead Sciences Details
    • 2.8.2 Gilead Sciences Major Business
    • 2.8.3 Gilead Sciences Radioimmunotherapy Product and Solutions
    • 2.8.4 Gilead Sciences Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Gilead Sciences Recent Developments and Future Plans
  • 2.9 Clarity Pharmaceuticals
    • 2.9.1 Clarity Pharmaceuticals Details
    • 2.9.2 Clarity Pharmaceuticals Major Business
    • 2.9.3 Clarity Pharmaceuticals Radioimmunotherapy Product and Solutions
    • 2.9.4 Clarity Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Clarity Pharmaceuticals Recent Developments and Future Plans
  • 2.10 Curasight
    • 2.10.1 Curasight Details
    • 2.10.2 Curasight Major Business
    • 2.10.3 Curasight Radioimmunotherapy Product and Solutions
    • 2.10.4 Curasight Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Curasight Recent Developments and Future Plans
  • 2.11 Nordic Nanovector
    • 2.11.1 Nordic Nanovector Details
    • 2.11.2 Nordic Nanovector Major Business
    • 2.11.3 Nordic Nanovector Radioimmunotherapy Product and Solutions
    • 2.11.4 Nordic Nanovector Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Nordic Nanovector Recent Developments and Future Plans
  • 2.12 Philogen
    • 2.12.1 Philogen Details
    • 2.12.2 Philogen Major Business
    • 2.12.3 Philogen Radioimmunotherapy Product and Solutions
    • 2.12.4 Philogen Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Philogen Recent Developments and Future Plans
  • 2.13 RadioMedix
    • 2.13.1 RadioMedix Details
    • 2.13.2 RadioMedix Major Business
    • 2.13.3 RadioMedix Radioimmunotherapy Product and Solutions
    • 2.13.4 RadioMedix Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 RadioMedix Recent Developments and Future Plans
  • 2.14 Telix Pharmaceuticals
    • 2.14.1 Telix Pharmaceuticals Details
    • 2.14.2 Telix Pharmaceuticals Major Business
    • 2.14.3 Telix Pharmaceuticals Radioimmunotherapy Product and Solutions
    • 2.14.4 Telix Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Telix Pharmaceuticals Recent Developments and Future Plans
  • 2.15 Orano Med
    • 2.15.1 Orano Med Details
    • 2.15.2 Orano Med Major Business
    • 2.15.3 Orano Med Radioimmunotherapy Product and Solutions
    • 2.15.4 Orano Med Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Orano Med Recent Developments and Future Plans
  • 2.16 Actinium Pharmaceuticals
    • 2.16.1 Actinium Pharmaceuticals Details
    • 2.16.2 Actinium Pharmaceuticals Major Business
    • 2.16.3 Actinium Pharmaceuticals Radioimmunotherapy Product and Solutions
    • 2.16.4 Actinium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Actinium Pharmaceuticals Recent Developments and Future Plans
  • 2.17 Y-mAbs Therapeutics
    • 2.17.1 Y-mAbs Therapeutics Details
    • 2.17.2 Y-mAbs Therapeutics Major Business
    • 2.17.3 Y-mAbs Therapeutics Radioimmunotherapy Product and Solutions
    • 2.17.4 Y-mAbs Therapeutics Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Y-mAbs Therapeutics Recent Developments and Future Plans
  • 2.18 Fusion Pharmaceuticals
    • 2.18.1 Fusion Pharmaceuticals Details
    • 2.18.2 Fusion Pharmaceuticals Major Business
    • 2.18.3 Fusion Pharmaceuticals Radioimmunotherapy Product and Solutions
    • 2.18.4 Fusion Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Fusion Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Radioimmunotherapy Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Radioimmunotherapy by Company Revenue
    • 3.2.2 Top 3 Radioimmunotherapy Players Market Share in 2025
    • 3.2.3 Top 6 Radioimmunotherapy Players Market Share in 2025
  • 3.3 Radioimmunotherapy Market: Overall Company Footprint Analysis
    • 3.3.1 Radioimmunotherapy Market: Region Footprint
    • 3.3.2 Radioimmunotherapy Market: Company Product Type Footprint
    • 3.3.3 Radioimmunotherapy Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Radioimmunotherapy Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Radioimmunotherapy Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Radioimmunotherapy Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Radioimmunotherapy Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Radioimmunotherapy Consumption Value by Type (2021-2032)
  • 6.2 North America Radioimmunotherapy Market Size by Application (2021-2032)
  • 6.3 North America Radioimmunotherapy Market Size by Country
    • 6.3.1 North America Radioimmunotherapy Consumption Value by Country (2021-2032)
    • 6.3.2 United States Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Radioimmunotherapy Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Radioimmunotherapy Consumption Value by Type (2021-2032)
  • 7.2 Europe Radioimmunotherapy Consumption Value by Application (2021-2032)
  • 7.3 Europe Radioimmunotherapy Market Size by Country
    • 7.3.1 Europe Radioimmunotherapy Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 7.3.3 France Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Radioimmunotherapy Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Radioimmunotherapy Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Radioimmunotherapy Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Radioimmunotherapy Market Size by Region
    • 8.3.1 Asia-Pacific Radioimmunotherapy Consumption Value by Region (2021-2032)
    • 8.3.2 China Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 8.3.5 India Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Radioimmunotherapy Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Radioimmunotherapy Consumption Value by Type (2021-2032)
  • 9.2 South America Radioimmunotherapy Consumption Value by Application (2021-2032)
  • 9.3 South America Radioimmunotherapy Market Size by Country
    • 9.3.1 South America Radioimmunotherapy Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Radioimmunotherapy Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Radioimmunotherapy Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Radioimmunotherapy Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Radioimmunotherapy Market Size by Country
    • 10.3.1 Middle East & Africa Radioimmunotherapy Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Radioimmunotherapy Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Radioimmunotherapy Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Radioimmunotherapy Market Drivers
  • 11.2 Radioimmunotherapy Market Restraints
  • 11.3 Radioimmunotherapy Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Radioimmunotherapy Industry Chain
  • 12.2 Radioimmunotherapy Upstream Analysis
  • 12.3 Radioimmunotherapy Midstream Analysis
  • 12.4 Radioimmunotherapy Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Radioimmunotherapy. Industry analysis & Market Report on Radioimmunotherapy is a syndicated market report, published as Global Radioimmunotherapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Radioimmunotherapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo